Research programme: kinase inhibitors - Plexxikon
Alternative Names: Omni-Raf inhibitors - Plexxikon; PLX-FK1; PLX4720Latest Information Update: 07 Jul 2022
At a glance
- Originator Plexxikon
- Developer OncoSec Medical; Plexxikon
- Class Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Macrophage colony-stimulating factor receptor antagonists; Proto-oncogene protein b-raf inhibitors; Proto-oncogene protein b-raf modulators; Raf kinase inhibitors; Vascular endothelial growth factor receptor-1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Cancer; Inflammation; Malignant melanoma; Multiple sclerosis; Polycystic kidney disease
Most Recent Events
- 06 Jul 2022 Discontinued - Preclinical for Alzheimer's disease in USA (PO)
- 06 Jul 2022 Discontinued - Preclinical for Cancer in USA (PO)
- 06 Jul 2022 Discontinued - Preclinical for Inflammation in USA (PO)